NCT07136805

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

A Multi-center, Randomized, Single-masked, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 1.0% VVN461 Ophthalmic Solution in Patients With Non-infectious Anterior Uveitis

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 152 (estimated)
• Sponsor: VivaVision Biotech, Inc · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China

Conditions

• Non-infectious Anterior Uveitis

Interventions

Type	Name	Description
DRUG	VVN461 Ophthalmic Solution 1.0%	1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
DRUG	1.0% prednisolone acetate	1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

Timeline

• Start date: 2025-10-01
• Primary completion: 2026-12-31
• Completion: 2027-04-30
• First posted: 2025-08-22
• Last updated: 2025-08-22

Regulatory

• FDA-regulated drug study